ReviewFrontiers in immunology2025
From ketogenic metabolism to targeted therapeutics: current advances in β-hydroxybutyrylation.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ketogenic Diet as an Adjuvant in Epithelial Cancers: Mechanisms, Model Systems, and Translational Opportunities.Cancers · 2026Review
- Metabolomic profiling reveals candidate biomarkers and key metabolic pathways associated with milk production performance in Sapera dairy goats.Veterinary world · 2026Article
- Ketogenic metabolic therapy as a candidate adjunct for CBTp delivery in schizophrenia spectrum disorders.Frontiers in psychology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-Hydroxybutyrylation (Kbhb) is a novel posttranslational modification (PTM) mediated by β-hydroxybutyrate (BHB). BHB, the core product of ketogenic metabolism, serves as its direct precursor and substrate. As a hub connecting energy metabolism and the epigenetic network, Kbhb exerts bidirectional regulatory effects on abnormal tumour metabolism, cardiovascular and cerebrovascular diseases, immune regulation, and other processes. Furthermore, Kbhb is not limited to histones; it is also widely present in nonhistones and influences various biological processes, such as protein stability, metabolic and energy homeostasis regulation, pathogen virulence regulation, transcriptional regulation, and signal transduction. This review summarizes the research progress in the field of Kbhb, including the inducers of Kbhb (ketogenic diet), prediction methods for modification sites (KbhbXG, pFunK, SLAM, iBhb-Lys), regulatory elements of modification (regulatory enzymes such as ENL and SIRT6, and protein substrates), mechanisms of action in cancer (e.g., mTOR signalling pathway, cGAS-STING signalling pathway), mechanisms of action in immune-related signalling pathways and immune-active components regulation, research progress on histone and nonhistone Kbhb (e.g., Bcl6, P53, STAT1, UvSlt2), and novel therapeutic strategies for diseases based on Kbhb modification (metabolic regulation and targeted therapy), providing new insights for targeted therapy for cancer and other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.